October 5, 2017 — External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of nonmelanoma skin cancer (NMSC) and early-stage breast cancer during the 2017 American Society for Radiation Oncology (ASTRO) meeting, Sept. 24-27 in San Diego. iCAD also hosted additional presentations and a series of peer-to-peer discussion opportunities with leading eBx experts at its booth.
In an oral presentation, Rakesh Patel, M.D., radiation oncologist at Precision Cancer Specialists, reviewed results from a study published in the Journal of Contemporary Brachytherapy comparing the use of the Xoft System and Mohs micrographic surgery for the treatment of NMSC.
“While Mohs surgery is considered the standard of care for NMSC, Xoft skin eBx represents an important option for many patients that can target the radiation dose directly to the cancerous site in a painless, non-invasive procedure,” said Patel. “We are excited to present these data, which add to a growing body of evidence indicating that eBx offers comparable results to Mohs surgery in appropriately selected early-stage NMSC patients.”
Nicholas Flores, M.D., director of radiation oncology at Arizona Dermatology, also presented data from a study of the treatment of peri-ocular NMSC using the Xoft System. From 2013 to 2016, Flores and fellow researchers treated 86 patients with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the eyelid with Xoft skin eBx. Results showed a 99 percent local control rate at two years post-treatment and no reported cases of side effects, such as long-term vision changes, dry eye, corneal injury, or retinitis.
Alam M. Nisar Syed, medical director, radiation oncology & endocurietherapy, MemorialCare Cancer Institute, Long Beach Memorial Medical Center, also presented data on the use of intraoperative radiation therapy (IORT) with the Xoft System in early-stage breast cancer patients. Syed discussed a non-randomized, prospective, multi-center trial that involved 1,076 patients with ductal carcinoma in situ (DCIS) or invasive ductal carcinoma who met specific selection criteria and received lumpectomy followed by IORT with the Xoft System. Results showed that Xoft IORT deliver low morbidity, excellent to good cosmetic results and a low rate of high-grade adverse events and recurrences in appropriate patients.
For more information: www.icadmed.com
September 12, 2025 
